Navigation Links
New ASCO/AUA guideline recommends men and their doctors discuss using 5-ARIs to reduce prostate cancer risk
Date:2/25/2009

ALEXANDRIA, Va. A newly released joint guideline produced by the American Society of Clinical Oncology (ASCO) and the American Urological Association (AUA) recommends that healthy men who are screened regularly for prostate cancer and show no symptoms of the disease should talk to their doctors about using a 5-alpha reductase inhibitor (5-ARI) to prevent the disease. 5-ARIs lower the level of the hormone dihydrotestosterone (DHT), which can contribute to the growth of prostate cancer.

This guideline aims to provide a useful tool for clinicians and their patients in making an informed decision about the potential benefits and risks of taking 5-ARIs for preventing prostate cancer and examines the use of 5-ARIs as a method of "chemoprevention" for prostate cancer. Chemoprevention is the use of a natural, synthetic or biologic substance to reverse, suppress or prevent the development of cancer. Currently, 5-ARIs are used to treat other non-cancerous conditions, such as male-pattern baldness and benign prostatic hyperplasia.

Prostate cancer is the most common non-skin cancer among men and the second-leading cause of cancer death in men. "Although one in every six men in the United States will be diagnosed with prostate cancer, we are not recommending that all men take 5-ARIs," said Barnett S. Kramer, MD, MPH, Associate Director for Disease Prevention at the National Institutes of Health and co-chair of the guideline panel. "However, we would encourage men to begin a dialogue with their doctors to determine if they could benefit from taking 5-ARIs to reduce their prostate cancer risk."

The key recommendations in the guideline include:

  • Men with a prostate-specific antigen (PSA) score of 3.0 or below who are screened regularly (or plan to get yearly PSA tests) and currently show no signs of prostate cancer are encouraged to talk with their doctor about the risks and benefits of taking a 5-ARI to further prevent their likelihood of getting prostate cancer

  • Men who are already taking a 5-ARI for other conditions should talk to their doctor about continuing to use this drug for the prevention of prostate cancer

The ASCO/AUA recommendations on chemoprevention for prostate cancer are based on evidence gathered from clinical trials, including the Prostate Cancer Prevention Trial (PCPT), in which participating men took a 5-ARI for one to seven years. Trial data showed an overall relative risk reduction of approximately 25 percent in most men who took a 5-ARI to prevent prostate cancer.

"Although a large clinical trial has shown that 5-ARIs can decrease the incidence of prostate cancer, we are still not able to determine if the mortality from prostate cancer is reduced," said Paul F. Schellhammer, MD, a past president of the AUA and co-chair of the panel that developed the guideline. "However, the demonstrated effect of 5-ARIs in reducing prostate cancer incidence makes it reasonable to recommend them for use to prevent the disease. But, as with any drug, patients should discuss the risks and benefits with their physicians."

In conjunction with this guideline, ASCO developed a Decision Aid Tool, which uses straightforward charts and diagrams to explain the risks and benefits of 5-ARIs to patients and their families. One section, called "Thinking It Over," encourages patients to discuss potential treatment decisions with their doctors and their family and determine what risks and benefits matter most to them.

The guideline will be published in the March issue of the Journal of Clinical Oncology and the March issue of The Journal of Urology. Along with the new guideline and the Decision Aid Tool, ASCO has released a corresponding patient guide available on ASCO's patient Web site, www.cancer.net.


'/>"/>

Contact: Lacey Dean
ldean@auanet.org
410-689-4054
American Urological Association
Source:Eurekalert

Related medicine news :

1. FDA Updates Prescription Guidelines for Blood Thinner
2. New Asthma Guidelines Stress Disease Control
3. Study finds primary care depression treatment often does not follow quality guidelines
4. New lung cancer guidelines oppose general CT screening
5. New Lung Cancer Guidelines Oppose General CT Screening
6. OSHA Issues Draft Ergonomics Guidelines on Preventing Musculoskeletal Injuries in Shipyards
7. Long-awaited international ethical guidelines for biobank researchers
8. Experts Publish New Lung Disease Guidelines
9. Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research
10. New guidelines set to improve standard of cows milk allergy care
11. GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... 2017 , ... Dudnyk has announced the launch of its new brand identity, ... potential of specialty and orphan brands can only be achieved when the needs and ... Effect is at the heart of a true partnership between our agency and our ...
(Date:4/21/2017)... ... April 21, 2017 , ... Crossover Symmetry , ... , an active lifestyle company that provides Human Performance Training and education to ... offers, first responders, military officers and others in service through the development and ...
(Date:4/21/2017)... UK (PRWEB) , ... April 21, 2017 , ... ... for Enterprise in the category of International Trade, the UK’s most prestigious award ... international trade, which represents 95% of total revenues and has grown by a ...
(Date:4/21/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, wrote an ... crisis with solution to peace plan. Yisrayl says war has never brought peace and he ... the Creator Himself. , Yisrayl says war drums are beating all over the media ...
(Date:4/21/2017)... ... 21, 2017 , ... Indiana Fiber Network, LLC (IFN), the ... to Tele-Media Solutions. IFN is delivering Multi-Gigabit data rates as an upstream ... protect transport with 3GB Dual Access Internet access now available in their service ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology: